HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

telmisartan (Micardis)

Subscribe to New Research on telmisartan

angiotensin II receptor antagonist; structure given in first source

Also Known As:

Micardis; Pritor; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; Abbott brand of telmisartan; BIBR 277; BIBR-277; Boehringer Ingelheim brand of telmisartan; Glaxo Wellcome brand of telmisartan; GlaxoSmithKline brand of telmisartan; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-

Networked: 869 relevant articles (159 outcomes, 370 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Yusuf, Salim: 33 articles (08/2015 - 01/2002)
2.	Teo, Koon: 18 articles (07/2015 - 07/2004)
3.	Schumacher, Helmut: 18 articles (03/2015 - 01/2002)
4.	Gao, Peggy: 16 articles (08/2015 - 10/2009)
5.	Sleight, Peter: 15 articles (06/2015 - 01/2002)
6.	Unger, Thomas: 15 articles (03/2015 - 05/2003)
7.	Mancia, Giuseppe: 13 articles (06/2015 - 01/2008)
8.	Teo, Koon K: 12 articles (08/2015 - 04/2008)
9.	Schmieder, Roland E: 12 articles (09/2011 - 11/2004)
10.	Anderson, Craig: 11 articles (07/2015 - 07/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 07/01/2004 - "In Japanese patients with mild-moderate hypertension, telmisartan produced a significant reduction in blood pressure (effective rate: 76.0%) with a good safety profile. " 01/01/2006 - "The consistent antihypertensive efficacy during the entire 24-hour dosage interval and sustained BP-lowering effect in the long term, combined with its favourable tolerability profile, mean that telmisartan is a valuable first-line treatment option for the management of essential hypertension." 07/01/2004 - "Therefore, telmisartan is expected to be effective in the treatment of hypertension, producing sustained 24-h blood pressure control." 03/01/2012 - "An effort was made to formulate a fast dissolving film containing telmisartan which is used in the treatment of hypertension with a view to improve the onset of action, therapeutic efficacy, patient compliance and convenience. " 12/01/2011 - "This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications. "
2.	Insulin Resistance 06/01/2012 - "FPI and insulin resistance may be improved with 80 mg of telmisartan." 01/01/2011 - "Treatment with telmisartan not only decreased SBP and DBP levels, but also improved insulin resistance and microalbuminuria by T1. " 01/01/2015 - "This trial will evaluate whether telmisartan can reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy. " 01/01/2015 - "Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy." 08/01/2014 - "A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients."
3.	Stroke (Strokes) 11/15/2009 - "Is telmisartan effective for stroke prevention?" 09/01/2012 - "This predefined substudy comprised 771 patients (mean age, 65 years) with recent ischemic stroke of noncardioembolic origin who received telmisartan or placebo during a mean follow-up of 27.9 (SD, 7.6) months and had 2 evaluable MRI examinations after index stroke and at study closeout. " 09/01/2012 - "We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. " 09/01/2009 - "A careful analysis of the PRoFESS trial, however, reveals study design limitations, the main one being that diastolic BP (<80 mmHg) in the first month post-stroke may have been too low in at least one third of the population with baseline systolic blood pressure less than 130 mmHg, because a high dose of telmisartan was given after a very short post-stroke delay (median 15 days) without discontinuation of the baseline antihypertensive treatment." 05/01/2009 - "Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?"
4.	Cardiovascular Diseases (Cardiovascular Disease) 06/01/2014 - "In the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease, all patients were at high cardiovascular risk, and a substantial proportion were hypertensive. " 06/01/2014 - "Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis." 09/01/2011 - "Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. " 01/01/2011 - "Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. " 01/01/2010 - "We therefore analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease). "
5.	Inflammation 01/01/2011 - "The present study was designed to evaluate the dose-response relationship of the anti-inflammatory activity of telmisartan in rat models of chronic inflammation. " 02/05/2015 - "Telmisartan treatment significantly prevented MAPK mediated inflammation and apoptosis. " 01/01/2015 - "Telmisartan could reduce inflammation. " 08/01/2013 - "Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats." 07/04/2013 - "Results clearly indicate that telmisartan significantly reduced the both oxidative and nitrosative stress, inflammation and cell death in diabetic testes. "

Related Drugs and Biologics

1.	Ramipril (Altace)
2.	Losartan (Cozaar)
3.	Hydrochlorothiazide (Esidrix)
4.	Angiotensin Receptors (Angiotensin II Receptor)
5.	Angiotensins
6.	Amlodipine (Norvasc)
7.	Enalapril
8.	Insulin (Novolin)
9.	PPAR gamma
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Oral Administration
2.	Ligation
3.	Renal Dialysis (Hemodialysis)
4.	Transplants (Transplant)
5.	Individualized Medicine